Choose language / Korean

Join Telegram

HanAll Biopharma Stock Surges 30% on Immunovant Clinical Trial Results
Bull/Bear Index 47.2/100
crypto BULL 35/10 TokenPost · 1h ago

HanAll Biopharma Stock Surges 30% on Immunovant Clinical Trial Results

HanAll Biopharma's stock rose by its daily limit on May 21st, driven by positive interim clinical trial results for a new drug candidate from its global partner, Immunovant.

Catch the next bull catalyst

Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 51.8%.

Join Telegram channel

Get high-impact news instantly

Top stories with score 8/10+ delivered to your Telegram in real time. Free.

Join Telegram channel

📡 Tomorrow's Watch

Related news


BEAR 55/10

An article from Bitcoin Magazine outlining 5 reasons why corporations should sell Bitcoin.

#crypto

BEAR 65/10

Ethereum price analysis suggests ETH is not merely pulling back but is breaking down, indicating a bearish trend.

#crypto

BULL 85/10

Bitcoin's long-term holder supply has increased by over 2 million coins.

#crypto

BULL 75/10

SpaceX is preparing for a landmark IPO, holding a significant $1.45 billion in Bitcoin as part of its treasury.

#crypto

55/10 +1

WEEX Report Highlights Ether’s Next Market Test as Ethereum Enters a New Post-ETF Phase

#crypto

BULL 40/10 +1

Michael Saylor of MicroStrategy stated his expectation that Bitcoin will outperform the S&P 500 over time, reiterating a bullish long-term outlook for Bitcoin.

#crypto